Tag - ATOS

Developments

Atossa, Quantum Leap in new study arm of I-SPY 2 clinical trial

Atossa Therapeutics (NASDAQ:ATOS) and Quantum Leap Healthcare Collaborative announced that Atossa’s proprietary selective estrogen receptor modulator, (Z)-endoxifen, will be evaluated in a new study arm of the ongoing I...

March 22, 2023

Developments

Atossa doses first patient in Phase 2 breast cancer study

Atossa Therapeutics (NASDAQ:ATOS) dosed the first patient in the Phase 2 EVANGELINE non-inferiority clinical trial of Atossa’s patented selective estrogen receptor modulator, (Z)-endoxifen, and exemestane plus goserelin...

February 23, 2023

Developments

Atossa to acquire stake in Dynamic Cell Therapies

Atossa Therapeutics (NASDAQ:ATOS) is acquiring 19.99% of the capital stock of closely-held Dynamic Cell Therapies for $2-million, in addition to $3-million previously paid to Dynamic, “This investment in Dynamic...

November 1, 2022

Feature

Atossa Therapeutics pivots inhalation therapy from COVID-19 to oncology

With widespread availability of SARS-CoV-2 vaccines and other therapies now approved to treat COVID-19, Atossa Therapeutics (NASDAQ:ATOS) has pivoted development of its AT-H201 inhalation therapy to cancer patients with...

October 25, 2022

Tag - ATOS

Atossa, Quantum Leap in new study arm of I-SPY 2 clinical trial

Atossa doses first patient in Phase 2 breast cancer study

Atossa to acquire stake in Dynamic Cell Therapies

Atossa Therapeutics pivots inhalation therapy from COVID-19 to oncology

General

More